当前位置: 首页 >> 检索结果
401. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
作者: Christoph Sarrazin.;Hadas Dvory-Sobol.;Evguenia S Svarovskaia.;Brian P Doehle.;Phillip S Pang.;Shu-Min Chuang.;Julie Ma.;Xiao Ding.;Nezam H Afdhal.;Kris V Kowdley.;Edward J Gane.;Eric Lawitz.;Diana M Brainard.;John G McHutchison.;Michael D Miller.;Hongmei Mo.
来源: Gastroenterology. 2016年151卷3期501-512.e1页
We evaluated the effects of baseline hepatitis C virus (HCV) NS5A, NS5B, and NS3 resistance-associated substitutions (RASs) on response to the combination of ledipasvir and sofosbuvir, with or without ribavirin, in patients with HCV genotype 1 infection.
402. Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial.
作者: Thiago Gagliano-Jucá.;Ronilson A Moreno.;Tiago Zaminelli.;Mauro Napolitano.;Antônio Frederico N Magalhães.;Aloísio Carvalhaes.;Miriam S Trevisan.;John L Wallace.;Gilberto De Nucci.
来源: BMC Gastroenterol. 2016年16卷1期58页
Rebamipide is a gastroprotective agent with promising results against gastric damage induced by non-steroidal anti-inflammatory drugs. The present study evaluated if rebamipide protects against naproxen-induced gastric damage in healthy volunteers. Changes in gastric PGE2 tissue concentration were also evaluated.
403. Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
作者: Edward J Gane.;Christian Schwabe.;Robert H Hyland.;Yin Yang.;Evguenia Svarovskaia.;Luisa M Stamm.;Diana M Brainard.;John G McHutchison.;Catherine A Stedman.
来源: Gastroenterology. 2016年151卷3期448-456.e1页
We performed a phase 2 trial of the efficacy and safety of 4, 6, and 8 weeks of sofosbuvir, given in combination with the NS5A inhibitor velpatasvir and the NS3/4A protease inhibitor GS-9857, in patients with hepatitis C virus (HCV) infection.
404. Endoscopic mucosal resection (EMR) versus endoscopic submucosal dissection (ESD) for resection of large distal non-pedunculated colorectal adenomas (MATILDA-trial): rationale and design of a multicenter randomized clinical trial.
作者: Y Backes.;L M G Moons.;J D van Bergeijk.;L Berk.;F Ter Borg.;P C J Ter Borg.;S G Elias.;J M J Geesing.;J N Groen.;M Hadithi.;J C H Hardwick.;M Kerkhof.;M J J Mangen.;J W A Straathof.;R Schröder.;M P Schwartz.;B W M Spanier.;W H de Vos Tot Nederveen Cappel.;F H J Wolfhagen.;A D Koch.
来源: BMC Gastroenterol. 2016年16卷1期56页
Endoscopic mucosal resection (EMR) is currently the most used technique for resection of large distal colorectal polyps. However, in large lesions EMR can often only be performed in a piecemeal fashion resulting in relatively low radical (R0)-resection rates and high recurrence rates. Endoscopic submucosal dissection (ESD) is a newer procedure that is more difficult resulting in a longer procedural time, but is promising due to the high en-bloc resection rates and the very low recurrence rates. We aim to evaluate the (cost-)effectiveness of ESD against EMR on both short (i.e. 6 months) and long-term (i.e. 36 months). We hypothesize that in the short-run ESD is more time consuming resulting in higher healthcare costs, but is (cost-) effective on the long-term due to lower patients burden, a higher number of R0-resections and lower recurrence rates with less need for repeated procedures.
405. Determination of the appropriate propofol infusion rate for outpatient upper gastrointestinal endoscopy-a randomized prospective study.
Pain and discomfort related to endoscopy sessions can be alleviated by sedation, which minimizes anxiety and allows safe examination. For outpatient endoscopy, reliable short-term sedation without secondary effects is required. This study aimed to assess the effects of intravenous propofol rates on sedation in outpatients undergoing upper gastrointestinal endoscopy.
406. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease.
作者: Ekkehard Bayerdörffer.;Marc-Andre Bigard.;Werner Weiss.;Fermín Mearin.;Luis Rodrigo.;Juan Enrique Dominguez Muñoz.;Hennie Grundling.;Tore Persson.;Lars-Erik Svedberg.;Nanna Keeling.;Stefan Eklund.
来源: BMC Gastroenterol. 2016年16卷48页
Most patients with gastroesophageal reflux disease experience symptomatic relapse after stopping acid-suppressive medication. The aim of this study was to compare willingness to continue treatment with esomeprazole on-demand versus continuous maintenance therapy for symptom control in patients with non-erosive reflux disease (NERD) after 6 months.
407. Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis.
作者: Anthony Lembo.;Michael Camilleri.;Richard McCallum.;Ramon Sastre.;Cristian Breton.;Sharon Spence.;Jeffery White.;Michelle Currie.;Keith Gottesdiener.;Elizabeth Stoner.; .
来源: Gastroenterology. 2016年151卷1期87-96.e6页
Gastroparesis is an important complication of diabetes. We investigated the effects of relamorelin (a pentapeptide-selective agonist of the ghrelin receptor that speeds gastric emptying in patients with diabetes) in patients with diabetic gastroparesis.
408. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
作者: Paul J Pockros.;K Rajender Reddy.;Parvez S Mantry.;Eric Cohen.;Michael Bennett.;Mark S Sulkowski.;David E Bernstein.;Daniel E Cohen.;Nancy S Shulman.;Deli Wang.;Amit Khatri.;Manal Abunimeh.;Thomas Podsadecki.;Eric Lawitz.
来源: Gastroenterology. 2016年150卷7期1590-1598页
Although hepatitis C virus (HCV) infection is common in patients with end-stage renal disease, highly efficacious, well-tolerated, direct-acting antiviral regimens have not been extensively studied in this population. We investigated the safety and efficacy of ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir (with or without ribavirin) in a prospective study of patients with stage 4 or 5 chronic kidney disease (CKD).
409. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
作者: Miguel Regueiro.;Brian G Feagan.;Bin Zou.;Jewel Johanns.;Marion A Blank.;Marc Chevrier.;Scott Plevy.;John Popp.;Freddy J Cornillie.;Milan Lukas.;Silvio Danese.;Paolo Gionchetti.;Stephen B Hanauer.;Walter Reinisch.;William J Sandborn.;Dario Sorrentino.;Paul Rutgeerts.; .
来源: Gastroenterology. 2016年150卷7期1568-1578页
Most patients with Crohn's disease (CD) eventually require an intestinal resection. However, CD frequently recurs after resection. We performed a randomized trial to compare the ability of infliximab vs placebo to prevent CD recurrence.
410. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
作者: Thomas D Boyer.;Arun J Sanyal.;Florence Wong.;R Todd Frederick.;John R Lake.;Jacqueline G O'Leary.;Daniel Ganger.;Khurram Jamil.;Stephen Chris Pappas.; .
来源: Gastroenterology. 2016年150卷7期1579-1589.e2页
Hepatorenal syndrome type 1 (HRS-1) in patients with cirrhosis and ascites is a functional, potentially reversible, form of acute kidney injury characterized by rapid (<2 wk) and progressive deterioration of renal function. Terlipressin is a synthetic vasopressin analogue that acts, via vascular vasopressin V1 receptors, as a systemic vasoconstrictor. We performed a phase 3 study to evaluate the efficacy and safety of intravenous terlipressin plus albumin vs placebo plus albumin in patients with HRS-1.
411. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
作者: Vlad Ratziu.;Stephen A Harrison.;Sven Francque.;Pierre Bedossa.;Philippe Lehert.;Lawrence Serfaty.;Manuel Romero-Gomez.;Jérôme Boursier.;Manal Abdelmalek.;Steve Caldwell.;Joost Drenth.;Quentin M Anstee.;Dean Hum.;Remy Hanf.;Alice Roudot.;Sophie Megnien.;Bart Staels.;Arun Sanyal.; .
来源: Gastroenterology. 2016年150卷5期1147-1159.e5页
Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).
412. A randomised controlled trial of a Mediterranean Dietary Intervention for Adults with Non Alcoholic Fatty Liver Disease (MEDINA): study protocol.
作者: Elena S Papamiltiadous.;Stuart K Roberts.;Amanda J Nicoll.;Marno C Ryan.;Catherine Itsiopoulos.;Agus Salim.;Audrey C Tierney.
来源: BMC Gastroenterol. 2016年16卷14页
Non-alcoholic fatty liver disease, the most prevalent liver disease in developed countries, remains difficult to manage with no proven safe and effective pharmacotherapy available. While weight reduction is the most commonly practiced treatment strategy, this is difficult to both achieve and/or maintain in the majority. Furthermore evidence-based dietary recommendations to guide the nutritional management of these patients are lacking. Using a randomised controlled trial design, this study compares the effectiveness of the Mediterranean diet to a standard low fat diet in terms of differences in insulin sensitivity, hepatic steatosis and metabolic outcomes in participants with non-alcoholic fatty liver disease.
413. Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients.
作者: John M Levenick.;Stuart R Gordon.;Linda L Fadden.;L Campbell Levy.;Matthew J Rockacy.;Sarah M Hyder.;Brian E Lacy.;Steven P Bensen.;Douglas D Parr.;Timothy B Gardner.
来源: Gastroenterology. 2016年150卷4期911-7; quiz e19页
Rectal indomethacin, a nonsteroidal anti-inflammatory drug, is given to prevent pancreatitis in high-risk patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), based on findings from clinical trials. The European Society for Gastrointestinal Endoscopy guidelines recently recommended prophylactic rectal indomethacin for all patients undergoing ERCP, including those at average risk for pancreatitis. We performed a randomized controlled trail to investigate the efficacy of this approach.
414. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis.
作者: Juan G Abraldes.;Candid Villanueva.;Carles Aracil.;Juan Turnes.;Manuel Hernandez-Guerra.;Joan Genesca.;Manuel Rodriguez.;Jose Castellote.;Juan Carlos García-Pagán.;Ferran Torres.;Jose Luis Calleja.;Agustin Albillos.;Jaime Bosch.; .
来源: Gastroenterology. 2016年150卷5期1160-1170.e3页
The combination of β-blockers and band ligation is the standard approach to prevent variceal rebleeding, but bleeding recurs and mortality is high. The lipid-lowering drug simvastatin decreases portal pressure, improves hepatocellular function, and might reduce liver fibrosis. We assessed whether adding simvastatin to standard therapy could reduce rebleeding and death after variceal bleeding in patients with cirrhosis.
415. Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids.
作者: Christophe Moreno.;Pierre Deltenre.;Christelle Senterre.;Alexandre Louvet.;Thierry Gustot.;Boris Bastens.;Axel Hittelet.;Marie-Astrid Piquet.;Wim Laleman.;Hans Orlent.;Luc Lasser.;Thomas Sersté.;Peter Starkel.;Xavier De Koninck.;Sergio Negrin Dastis.;Jean Delwaide.;Isabelle Colle.;Chantal de Galocsy.;Sven Francque.;Philippe Langlet.;Virginie Putzeys.;Hendrik Reynaert.;Delphine Degré.;Eric Trépo.
来源: Gastroenterology. 2016年150卷4期903-10.e8页
Severe alcoholic hepatitis (AH) is a life-threatening disease for which adequate oral nutritional support is recommended. We performed a randomized controlled trial to determine whether the combination of corticosteroid and intensive enteral nutrition therapy is more effective than corticosteroid therapy alone in patients with severe AH.
416. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome.
作者: Mira M Wouters.;Dafne Balemans.;Sander Van Wanrooy.;James Dooley.;Vincent Cibert-Goton.;Yeranddy A Alpizar.;Eduardo E Valdez-Morales.;Yasmin Nasser.;Paul P Van Veldhoven.;Winde Vanbrabant.;Schalk Van der Merwe.;Raf Mols.;Bart Ghesquière.;Carla Cirillo.;Inge Kortekaas.;Peter Carmeliet.;Willy E Peetermans.;Séverine Vermeire.;Paul Rutgeerts.;Patrick Augustijns.;Peter W Hellings.;Ann Belmans.;Stephen Vanner.;David C Bulmer.;Karel Talavera.;Pieter Vanden Berghe.;Adrian Liston.;Guy E Boeckxstaens.
来源: Gastroenterology. 2016年150卷4期875-87.e9页
Histamine sensitizes the nociceptor transient reporter potential channel V1 (TRPV1) and has been shown to contribute to visceral hypersensitivity in animals. We investigated the role of TRPV1 in irritable bowel syndrome (IBS) and evaluated if an antagonist of histamine receptor H1 (HRH1) could reduce symptoms of patients in a randomized placebo-controlled trial.
417. Design of a dietary intervention to assess the impact of a gluten-free diet in a population with type 1 Diabetes and Celiac Disease.
作者: Esther Assor.;Margaret A Marcon.;Natasha Hamilton.;Marilyn Fry.;Tammy Cooper.;Farid H Mahmud.
来源: BMC Gastroenterol. 2015年15卷181页
Celiac Disease occurs at a 5-10 fold greater prevalence in patients with type-1 diabetes (T1D), despite this increased risk, there is limited objective evidence regarding the impact of a Gluten-Free Diet (GFD) in the large proportion of asymptomatic (30-70%) patients with both autoimmune diseases. Given the requirements and intricacies inherent to each condition, we describe the rationale and design a dietary curriculum specifically addressing the educational requirements for children and adults with CD and diabetes as part of the CD-DIET Study.
418. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
作者: Jennifer E Lambert.;Jill A Parnell.;Bertus Eksteen.;Maitreyi Raman.;Marc R Bomhof.;Kevin P Rioux.;Karen L Madsen.;Raylene A Reimer.
来源: BMC Gastroenterol. 2015年15卷169页
Evidence for the role of the gut microbiome in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) is emerging. Strategies to manipulate the gut microbiota towards a healthier community structure are actively being investigated. Based on their ability to favorably modulate the gut microbiota, prebiotics may provide an inexpensive yet effective dietary treatment for NAFLD. Additionally, prebiotics have established benefits for glucose control and potentially weight control, both advantageous in managing fatty liver disease. Our objective is to evaluate the effects of prebiotic supplementation, adjunct to those achieved with diet-induced weight loss, on heptic injury and liver fat, the gut microbiota, inflammation, glucose tolerance, and satiety in patients with NAFLD.
419. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
作者: Franck Carbonnel.;Jean Frédéric Colombel.;Jérome Filippi.;Konstantinos H Katsanos.;Laurent Peyrin-Biroulet.;Mathieu Allez.;Maria Nachury.;Gottfried Novacek.;Silvio Danese.;Vered Abitbol.;Fabrizio Bossa.;Jacques Moreau.;Gilles Bommelaer.;Arnaud Bourreille.;Mathurin Fumery.;Xavier Roblin.;Walter Reinisch.;Yoram Bouhnik.;Hedia Brixi.;Philippe Seksik.;Georgia Malamut.;Martti Färkkilä.;Baya Coulibaly.;Olivier Dewit.;Edouard Louis.;Dominique Deplanque.;Pierre Michetti.;Hélène Sarter.;David Laharie.; .; .
来源: Gastroenterology. 2016年150卷2期380-8.e4页
Parenteral methotrexate is an effective treatment for patients with Crohn's disease, but has never been adequately evaluated in patients with ulcerative colitis (UC). We conducted a randomized controlled trial to determine its safety and efficacy in patients with steroid-dependent UC.
420. An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease.
作者: Naoki Yoshimura.;Yoko Yokoyama.;Katsuyoshi Matsuoka.;Hiroki Takahashi.;Ryuichi Iwakiri.;Takayuki Yamamoto.;Tomoo Nakagawa.;Takumi Fukuchi.;Satoshi Motoya.;Reiko Kunisaki.;Shingo Kato.;Fumihito Hirai.;Yoh Ishiguro.;Satoshi Tanida.;Sakiko Hiraoka.;Keiichi Mitsuyama.;Shunji Ishihara.;Shinji Tanaka.;Michiro Otaka.;Taro Osada.;Takashi Kagaya.;Yasuo Suzuki.;Hiroshi Nakase.;Hiroyuki Hanai.;Kenji Watanabe.;Nobuhito Kashiwagi.;Toshifumi Hibi.
来源: BMC Gastroenterol. 2015年15卷163页
Granulocyte and monocyte adsorptive apheresis (GMA) has shown efficacy in patients with active Crohn's disease (CD). However, with routine weekly therapy, it may take several weeks to achieve remission. This study was performed to assess clinical efficacy and safety of intensive GMA in patients with active CD.
|